Robbert J. de Winter1, MD, PhD; Azfar Zaman2, MD; Hironori Hara1,3, MD; Chao Gao3,4, MD; Masafumi Ono1,3, MD; Scot Garg5, MD, PhD; Pieter C. Smits6, MD, PhD; Pim A.L. Tonino7, MD, PhD; Sjoerd H. Hofma8, MD, PhD; Raul Moreno9, MD, PhD; Anirban Choudhury10, MD; Ivo Petrov11, MD; Angel Cequier12, MD; Antonio Colombo13,14, MD; Upendra Kaul15, MD, PhD; Yoshinobu Onuma3, MD, PhD; Patrick W. Serruys3,16, MD, PhD
1. Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 2. Newcastle Freeman Hospital, Newcastle University, and Newcastle upon Tyne Hospitals NHS Trust, Newcastle, United Kingdom; 3. Department of Cardiology, National University of Ireland Galway, Galway, Ireland; 4. Department of Cardiology, Radboud University, Nijmegen, the Netherlands; 5. Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom; 6. Maasstad Ziekenhuis, Rotterdam, the Netherlands; 7. Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands; 8. Medical Centre Leeuwarden, Leeuwarden, the Netherlands; 9. Cardiology Department, La Paz University Hospital, Madrid, Spain; 10. Department of Cardiology, University Hospital of Wales, Cardiff, United Kingdom; 11. Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria; 12. Bellvitge University Hospital, University of Barcelona, IDIBELL, Barcelona, Spain; 13. Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy; 14. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 15. Academics and Research, Batra Hospital and Medical Research Center, New Delhi, India; 16. NHLI, Imperial College London, London, United Kingdom
Background: In the TALENT study, the sirolimus-eluting ultrathin strut Supraflex stent was non-inferior to the XIENCE stent for a device-oriented composite endpoint (DoCE: defined as cardiac death, target vessel myocardial infarction [TV-MI], or clinically indicated target lesion revascularisation [CI-TLR]) at 12 months.
Aims: This study investigated the 3-year outcomes of the TALENT trial and long-term impact of ultrathin drug-eluting stents (DES), compared to the XIENCE everolimus-eluting thin stent.
Methods: The TALENT trial is a prospective, multicentre, randomised all-comers trial comparing the Supraflex sirolimus-eluting stent with the XIENCE everolimus-eluting stent, with planned follow-up for 3 years.
Results: The TALENT trial enrolled 1,435 patients (Supraflex n=720, XIENCE n=715) with 3-year follow-up data available in 97.8% in the Supraflex group, and in 98.9% in the XIENCE group. At 3 years, DoCE occurred in 57 patients (8.1%) in the Supraflex group, and in 66 patients (9.4%) in the XIENCE group (p=0.406). There were no significant between-group differences in rates of cardiac death, TV-MI or CI-TLR. The rates of definite or probable stent thrombosis were low and similar between groups (1.1% vs 1.4%; p=0.640). In a meta-analysis of long-term follow-up (3-5 years), ultrathin strut DES tended to reduce DoCE (relative risk 0.89 [0.79-1.01]; p=0.068), compared to thicker strut DES. The risks for cardiac death and definite or probable stent thrombosis were similar between ultrathin strut DES and thicker strut DES.
Conclusions: At 3-year follow-up, the use of the Supraflex stent was at least as safe and efficacious as the XIENCE stent in an all-comers population. ClinicalTrials.gov: NCT02870140
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
clinical trialsdrug-eluting stentinnovation
Read next article
Bleeding risk differences after TAVR according to the ARC-HBR criteria: insights from SCOPE 2